Modified Citrus Pectin Benefits Cancer

FREIBURG,Germany—In a recent pilot trial at Albert-Ludwigs University, modified citrus pectin (MCP) showed a positive impact on life quality for patients with far advanced solid tumors (Clin Med: Oncol. 2007;1:73-80). Forty-nine patients with various solid tumors in an advanced state of progression received oral intake of 5 g of MCP (as PectaSol-C, from EcoNugenics) three times daily. One cycle of therapy was defined as four weeks of treatment. After two cycles of MCP treatment, 29 patients were able to be evaluated; 20.7 percent had an overall clinical response associated with a stabilization or improvement on life quality, 22.5 percent showed a stable disease after two cycles, and 12.3 percent had a stable disease for a period longer than 24 weeks.